PeptideX Blog

A deep dive into peptide stacking protocols — the Wolverine stack (BPC-157 & TB-500), growth hormone synergy (CJC-1295 & Ipamorelin), longevity and cognitive stacks, and how to combine compounds effectively.

A comprehensive analysis of the 2026 FDA peptide reclassification — which 14 peptides are returning to Category 1, what it means for patients and providers, and how to navigate peptide therapy safely.

A head-to-head comparison of semaglutide and tirzepatide — mechanisms, clinical trial data, weight loss efficacy, side effect profiles, and which GLP-1 performs better.

A comprehensive research guide to retatrutide — the first GLP-1/GIP/glucagon triple receptor agonist, its Phase 3 trial status, and what it means for the future of metabolic medicine.

A research-backed safety analysis of popular peptides including BPC-157, semaglutide, and GHK-Cu — covering clinical safety data, purity risks, and side effect profiles.

A research-backed comparison of the best peptides for muscle growth including CJC-1295, Ipamorelin, MK-677, Follistatin-344, and IGF-1 LR3.

A research-backed comparison of MK-677 (ibutamoren) vs ipamorelin — oral vs injectable GH secretagogues compared on mechanism, side effects, and stacking.

A research-backed comparison of CJC-1295 and Sermorelin — two GHRH analogs for growth hormone optimization. DAC vs no-DAC, dosing, and clinical outcomes.

A research-backed guide to peptide stacking — principles of safe combination, popular stacks for recovery, body composition, and longevity, timing, and contraindications.

A deep dive into MOTS-c — the mitochondrial-derived peptide that mimics exercise, activates AMPK, and shows remarkable potential for metabolic regulation and longevity.

A research-backed comparison of oral vs injectable peptide delivery — bioavailability, SNAC technology, orforglipron, and the future of oral peptide formulations.

The FDA is reclassifying 14 restricted peptides from Category 2 back to Category 1. What it means for patients, clinics, and the future of peptide therapy.

An independent analysis of the recent FDA approvals for oral GLP-1 and small-molecule peptide therapeutics, and what they mean for the future of longevity and weight loss.

An independent analysis of GHK-Cu, the copper tripeptide seeing a 1,000% surge in anti-aging, longevity, and skin regeneration research in 2026.

An in-depth analysis of the synergistic mechanisms between BPC-157 and TB-500 for musculoskeletal tissue repair and inflammation reduction.

Comparing GLP-1 agonists, AOD-9604, and MOTS-c across clinical trials to determine the most effective peptide pathways for lipid oxidation.

Avoid dangerous synthesis byproducts by learning how to properly analyze independent HPLC and mass spectrometry reports before sourcing.

Understanding the synergistic GHRP and GHRH relationship that maximizes endogenous growth hormone pulses without cortisol spikes.

Navigating the complex regulatory landscape of purchasing, owning, and researching peptides across North America, Europe, and Australia.

We independently evaluate peptide vendors based on third-party COA testing, purity verification, shipping speed, and pricing. Updated monthly for April 2026.